Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Abbott Laboratories : Abbott and AbbVie Announce Investor Calls

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2013 | 04:10pm CET

Abbott Park, Illinois and North Chicago - Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2012 financial results on Wednesday, Jan. 23, 2013, before the market opens.

Abbott's quarterly and annual results will include contributions from the company's former research-based pharmaceutical business, which became AbbVie on Jan. 1, 2013. While these results will be captured in a single press release, both companies will host separate conference calls to discuss their respective business results and 2013 outlooks.

Abbott will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) on Jan. 23, 2013. It will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

On Wednesday, Jan. 30, 2013, AbbVie will host a live webcast at 8 a.m. Central time (9 a.m. Eastern) accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Abbott Contacts:
Media:
Scott Stoffel

(847) 936-9502
Financial:
Brian Yoor

(847) 937-6343
AbbVie Contacts:
Media:
Adelle Infante

(847) 938-8745
Financial:
Larry Peepo

(847) 935-6722
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
11/16 ABBOTT LABORATORIES : An Application for the Trademark "NURSE CURRENTS" Has Been..
11/16 ABBOTT LABORATORIES : An Application for the Trademark "THERAPEUTIC HYDRATION TO..
11/16 ABBOTT LABORATORIES : ' Trademark Application for "DIETETIC CURRENTS" Filed
11/16 ABBOTT LABORATORIES : An Application for the Trademark "EAS PHOS FORCE" Has Been..
11/15 HANGER,INC. (OTCMKTS : HNGR) Files An 8-K Departure of Directors or Certain Offi..
11/09 ABBOTT LABORATORIES : An Application for the Trademark "LIQUI-MIX SYSTEM" Has Be..
11/09 ABBOTT LABORATORIES : Mitraclip approved as first transcatheter mitral valve rep..
11/08 ABBOTT LABORATORIES : Federal Contracts Awarded by Federal Agencies in South Dak..
11/08 ABBOTT LABORATORIES : $28,890 Federal Contract Awarded to Abbott Laboratories
11/08 ABBOTT LABORATORIES : Chicagoland Chamber names Jack Lavin president and CEO
More news
News from SeekingAlpha
11/17 Thursday Was About Wal-Mart And Cisco - Cramer's Mad Money (11/16/17)
11/17 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2017 Update
11/17 DIVIDEND CHALLENGERS (AND NEAR-CHALL : 58 Increases Expected By The End Of Janua..
11/15 5 Reasons To Buy The Dip - Cramer's Mad Money (11/14/17)
11/06 EQUITY CEFS : Help! My Fund Has Been Ama-Zonked!
Financials ($)
Sales 2017 27 185 M
EBIT 2017 6 008 M
Net income 2017 2 227 M
Debt 2017 19 729 M
Yield 2017 1,93%
P/E ratio 2017 47,08
P/E ratio 2018 35,13
EV / Sales 2017 4,28x
EV / Sales 2018 3,78x
Capitalization 96 708 M
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 61,6 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES44.65%96 708
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550